Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Pfizer Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = ROA × Financial Leverage
Mar 29, 2026 = ×
Dec 31, 2025 = ×
Sep 28, 2025 = ×
Jun 29, 2025 = ×
Mar 30, 2025 = ×
Dec 31, 2024 = ×
Sep 29, 2024 = ×
Jun 30, 2024 = ×
Mar 31, 2024 = ×
Dec 31, 2023 = ×
Oct 1, 2023 = ×
Jul 2, 2023 = ×
Apr 2, 2023 = ×
Dec 31, 2022 = ×
Oct 2, 2022 = ×
Jul 3, 2022 = ×
Apr 3, 2022 = ×

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The analysis of the two-component DuPont disaggregation reveals a significant volatility in Return on Equity (ROE), primarily driven by fluctuations in Return on Assets (ROA), while financial leverage remained relatively stable throughout the period.

Return on Equity (ROE) Trajectory
ROE exhibited a precipitous decline from a peak of 33.61% in July 2022 to a trough of -2.96% by June 30, 2024. Following this low point, a recovery phase is observed, with ROE ascending to 12.12% by June 29, 2025, before stabilizing between 8.31% and 8.99% in the final quarters of the analyzed period.
Return on Assets (ROA) Performance
The ROA serves as the primary catalyst for the observed changes in ROE. Asset productivity was strongest in 2022, peaking at 15.91% in December. A severe contraction occurred throughout 2023, leading to negative returns in the first half of 2024, reaching -1.20% in June 2024. A subsequent recovery saw ROA return to positive territory, peaking at 5.22% in June 2025 and eventually settling around 3.61% by March 29, 2026.
Financial Leverage Stability
Financial leverage remained a consistent multiplier, fluctuating within a narrow range between 1.94 and 2.54. A gradual increase in leverage was noted from April 2023 (1.94) to December 2023 (2.54), suggesting a slight increase in the use of debt to amplify returns. However, the leverage ratio stabilized between 2.25 and 2.42 from 2024 through early 2026, indicating that the dramatic swings in ROE were not caused by changes in capital structure but by underlying operational profitability.
Correlation and Synthesis
The synchronization between ROA and ROE confirms that the company's equity returns are almost entirely dependent on asset efficiency. While financial leverage provided a consistent amplification effect (typically doubling the ROA), it was insufficient to offset the sharp decline in asset returns during 2023 and early 2024. The recovery in ROE observed in 2025 is directly attributable to the restoration of positive ROA.

Three-Component Disaggregation of ROE

Pfizer Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Mar 29, 2026 = × ×
Dec 31, 2025 = × ×
Sep 28, 2025 = × ×
Jun 29, 2025 = × ×
Mar 30, 2025 = × ×
Dec 31, 2024 = × ×
Sep 29, 2024 = × ×
Jun 30, 2024 = × ×
Mar 31, 2024 = × ×
Dec 31, 2023 = × ×
Oct 1, 2023 = × ×
Jul 2, 2023 = × ×
Apr 2, 2023 = × ×
Dec 31, 2022 = × ×
Oct 2, 2022 = × ×
Jul 3, 2022 = × ×
Apr 3, 2022 = × ×

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The Return on Equity (ROE) exhibited significant volatility over the analyzed period, characterized by a steep decline from peaks exceeding 33% in mid-2022 to a negative trough in mid-2024, followed by a gradual recovery toward a stabilized range of 8% to 12% by early 2026.

Net Profit Margin
Profitability served as the primary driver of ROE volatility. Margins peaked at 31.27% in December 2022 before entering a severe contraction phase, reaching a low of -4.62% by June 2024. A subsequent recovery occurred throughout late 2024 and 2025, with margins stabilizing between 11.83% and 16.84%. This pattern indicates a period of significant earnings compression followed by a return to positive, albeit lower, profitability levels compared to 2022.
Asset Turnover
Asset utilization efficiency followed a similar downward trajectory to profitability. The turnover ratio decreased from a high of 0.52 in July 2022 to a minimum of 0.25 in March 2024. From mid-2024 through early 2026, the ratio stabilized around 0.30, suggesting that the company experienced a period of diminished asset productivity that partially recovered but did not return to 2022 levels.
Financial Leverage
Financial leverage remained the most stable component of the DuPont analysis, fluctuating within a narrow band between 1.94 and 2.54. A peak in leverage occurred in December 2023 at 2.54, coinciding with the period of lowest profitability. This suggests that increased reliance on debt was employed to support operations or maintain equity returns as margins and asset turnover declined.

The synthesis of these components reveals that the collapse in ROE between 2022 and 2024 was a dual result of crashing profit margins and declining asset efficiency. While financial leverage remained relatively constant and provided a modest multiplier effect, it was insufficient to offset the sharp deterioration in operational performance. The recovery observed from late 2024 onward was driven predominantly by the restoration of positive net profit margins and a slight improvement in asset turnover.


Two-Component Disaggregation of ROA

Pfizer Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Mar 29, 2026 = ×
Dec 31, 2025 = ×
Sep 28, 2025 = ×
Jun 29, 2025 = ×
Mar 30, 2025 = ×
Dec 31, 2024 = ×
Sep 29, 2024 = ×
Jun 30, 2024 = ×
Mar 31, 2024 = ×
Dec 31, 2023 = ×
Oct 1, 2023 = ×
Jul 2, 2023 = ×
Apr 2, 2023 = ×
Dec 31, 2022 = ×
Oct 2, 2022 = ×
Jul 3, 2022 = ×
Apr 3, 2022 = ×

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The analysis of Return on Assets (ROA) reveals a cyclical trajectory characterized by an initial period of strength, a severe contraction into negative territory, and a subsequent partial recovery. The overall trend indicates that both profitability and asset utilization experienced significant volatility between mid-2023 and mid-2024.

Net Profit Margin
Profitability exhibited extreme fluctuations, peaking at 31.27% in December 2022 before entering a steep descent. The margin collapsed to 3.56% by December 2023 and reached its nadir at -4.62% in June 2024. A recovery phase ensued, with margins ascending to a secondary peak of 16.84% in June 2025, before stabilizing between 11% and 12% through March 2026.
Asset Turnover
Asset efficiency demonstrated a steady decline from a high of 0.52 in July 2022 to a low of 0.25 in March 2024. Following this period of erosion, the ratio stabilized, fluctuating within a tight range of 0.26 to 0.31 through the end of the period. This suggests a fundamental shift in the revenue-generating capacity of the asset base compared to the levels observed in 2022.
Return on Assets (ROA) Synthesis
The ROA trajectory was primarily driven by the volatility of the net profit margin, though the decline was compounded by the simultaneous reduction in asset turnover. The peak ROA of 15.91% recorded in December 2022 plummeted to a minimum of -1.20% in June 2024. Although ROA recovered to 5.22% by June 2025, the final value of 3.61% in March 2026 indicates that the recovery remained modest relative to the 2022 baseline, reflecting the combined impact of normalized margins and lower asset efficiency.